- BARD1 Life Sciences (BD1) enters a trading halt while it plans a capital raise
- BARD1 is a diagnostics company who is focussed on developing and commercialising four technologies to detect various cancers earlier on
- At this stage, it isn’t certain how much the healthcare stock is looking to raise or what it will use the money for
- But the market will only have to wait until Friday, July 23, at the latest to find out
- BARD1’s shares last traded at $1.80 on Tuesday, July 20
BARD1 Life Sciences (BD1) has entered a trading halt while it plans a capital raise.
BARD1 is a diagnostics company who’s focussed on early detection of various cancers including breast, prostate, ovarian and pancreatic cancer.
At this stage, it isn’t certain how much the healthcare stock is looking to raise or what it will use the money for.
The company is focussed on developing and commercialising its four technology platforms: SubB2M, NETS, BARD1 and hTERT. BARD1 claims these core technologies are ‘game-changers’ for detecting different cancers early on.
In terms of recent news flow, BARD1 announced its auto-antibody test results for ovarian cancer was published in an international, peer-reviewed journal.
The data conveyed positive results from its OC-CA125 and OC-R001 studies in ovarian cancer using its BARD1-Ovarian blood test. These studies took place at the University of Geneva under a research agreement.
The company’s shares will remain in a trading halt until no later than Friday, July 23, by which time the details of the capital raise would have been released.
BARD1’s shares last traded at $1.80 on Tuesday, July 20.